Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.

Article  PubMed  PubMed Central  Google Scholar 

Rohatgi A, Westerterp M, von Eckardstein A, Remaley A, Rye KA. HDL in the 21st Century: A multifunctional roadmap for future HDL research. Circulation. 2021;143(23):2293–309. https://doi.org/10.1161/circulationaha.120.044221.

Article  PubMed  PubMed Central  Google Scholar 

Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966;34(4):679–97. https://doi.org/10.1161/01.cir.34.4.679.

Article  CAS  PubMed  Google Scholar 

Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease The cooperative lipoprotein phenotyping study. Circulation. 1977;55(5):767–72. https://doi.org/10.1161/01.cir.55.5.767.

Article  CAS  PubMed  Google Scholar 

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease the framingham study. Am J Med. 1977;62(5):707–14. https://doi.org/10.1016/0002-9343(77)90874-9.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933–42. https://doi.org/10.1056/NEJMoa1609581.

Article  PubMed  Google Scholar 

Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27. https://doi.org/10.1056/NEJMoa1706444.

Article  PubMed  Google Scholar 

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. https://doi.org/10.1056/NEJMoa1206797.

Article  CAS  PubMed  Google Scholar 

Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. https://doi.org/10.1056/NEJMoa1107579.

Article  CAS  PubMed  Google Scholar 

Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12. https://doi.org/10.1056/NEJMoa1300955.

Article  CAS  PubMed  Google Scholar 

Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923–34. https://doi.org/10.1056/NEJMoa2210645.

Article  PubMed  Google Scholar 

Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919–31. https://doi.org/10.1093/cvr/cvab350.

Article  CAS  PubMed  Google Scholar 

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80. https://doi.org/10.1016/s0140-6736(12)60312-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97(2):E248–56. https://doi.org/10.1210/jc.2011-1846.

Article  CAS  PubMed  Google Scholar 

Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50. https://doi.org/10.1093/eurheartj/eht571.

Article  CAS  PubMed  Google Scholar 

Karjalainen MK, Holmes MV, Wang Q, Anufrieva O, Kähönen M, Lehtimäki T, et al. Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. Atherosclerosis. 2020;299:56–63. https://doi.org/10.1016/j.atherosclerosis.2020.02.002.

Article  CAS  PubMed  Google Scholar 

Zhong GC, Huang SQ, Peng Y, Wan L, Wu YQ, Hu TY, et al. HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. Eur J Prev Cardiol. 2020;27(11):1187–203. https://doi.org/10.1177/2047487320914756.

Article  PubMed  Google Scholar 

Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations. JAMA Cardiol. 2022;7(7):672–80. https://doi.org/10.1001/jamacardio.2022.0912.

Article  PubMed  PubMed Central  Google Scholar 

Mamede I, Braga MAP, Martins OC, Franchini AEO, Silveira Filho RB, Santos MCF. Association between very high HDL-C levels and mortality: A systematic review and meta-analysis. J Clin Lipidol. 2024;18(5):e701–9. https://doi.org/10.1016/j.jacl.2024.06.002.

Article  PubMed  Google Scholar 

Allard-Ratick MP, Kindya BR, Khambhati J, Engels MC, Sandesara PB, Rosenson RS, et al. HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. Eur J Prev Cardiol. 2021;28(2):166–73. https://doi.org/10.1177/2047487319848214.

Article  PubMed  Google Scholar 

Linton MF, Yancey PG, Tao H, Davies SS. HDL function and atherosclerosis: Reactive dicarbonyls as promising targets of therapy. Circ Res. 2023;132(11):1521–45. https://doi.org/10.1161/circresaha.123.321563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: An analysis from the jupiter trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). Circulation. 2017;135(25):2494–504. https://doi.org/10.1161/circulationaha.116.025678.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JJ, Chi G, Fitzgerald C, Kazmi SHA, Kalayci A, Korjian S, et al. Cholesterol efflux capacity and its association with adverse cardiovascular events: A systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:774418. https://doi.org/10.3389/fcvm.2021.774418.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh K, Chandra A, Sperry T, Joshi PH, Khera A, Virani SS, et al. Associations between high-density lipoprotein particles and ischemic events by vascular domain, sex, and ethnicity: A pooled cohort analysis. Circulation. 2020;142(7):657–69. https://doi.org/10.1161/circulationaha.120.045713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ditah C, Otvos J, Nassar H, Shaham D, Sinnreich R, Kark JD. Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample. Atherosclerosis. 2016;251:124–31. https://doi.org/10.1016/j.atherosclerosis.2016.06.010.

Article  CAS  PubMed  Google Scholar 

Ajala ON, Demler OV, Liu Y, Farukhi Z, Adelman SJ, Collins HL, et al. Anti-Inflammatory HDL function, incident cardiovascular events, and mortality: A secondary analysis of the Jupiter randomized clinical trial. J Am Heart Assoc. 2020;9(17):e016507. https://doi.org/10.1161/jaha.119.016507.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soria-Florido MT, Schröder H, Grau M, Fitó M, Lassale C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis. 2020;302:36–42. https://doi.org/10.1016/j.atherosclerosis.2020.04.015.